Citigroup Inc Y M Abs Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 8,969 shares of YMAB stock, worth $116,148. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,969

Previous 6,745 32.97%

Holding current value

$116,148

Previous $109,000 0.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$11.6 - $17.25 $25,798 - $38,364	2,224 Added 32.97%	8,969 $108,000
Q1 2024 May 10, 2024	BUY	$6.57 - $18.69 $4,822 - $13,718	734 Added 12.21%	6,745 $109,000
Q4 2023 Feb 09, 2024	BUY	$4.88 - $7.42 $29,240 - $44,460	5,992 Added 31536.84%	6,011 $40,000
Q3 2023 Nov 09, 2023	SELL	$4.86 - $7.23 $53,148 - $79,067	-10,936 Reduced 99.83%	19 $0
Q2 2023 Aug 10, 2023	SELL	$5.68 - $10.34 $203,838 - $371,071	-35,887 Reduced 76.61%	10,955 $74,000
Q1 2023 May 11, 2023	BUY	$2.83 - $5.11 $129,554 - $233,930	45,779 Added 4306.59%	46,842 $234,000
Q4 2022 Feb 09, 2023	SELL	$3.0 - $15.17 $279,651 - $1.41 Million	-93,217 Reduced 98.87%	1,063 $5,000
Q3 2022 Nov 10, 2022	BUY	$13.96 - $19.67 $493,541 - $695,413	35,354 Added 60.0%	94,280 $1.36 Million
Q2 2022 Aug 10, 2022	BUY	$8.22 - $15.13 $234,467 - $431,568	28,524 Added 93.82%	58,926 $891,000
Q1 2022 May 12, 2022	SELL	$6.55 - $17.42 $244,662 - $650,689	-37,353 Reduced 55.13%	30,402 $361,000
Q4 2021 Feb 10, 2022	BUY	$15.51 - $29.31 $558,344 - $1.06 Million	35,999 Added 113.36%	67,755 $1.1 Million
Q3 2021 Nov 10, 2021	BUY	$27.47 - $37.31 $872,337 - $1.18 Million	31,756 New	31,756 $906,000

Others Institutions Holding YMAB

# of Institutions

Shares Held

23.8M

Call Options Held

19.4K

Put Options Held

300

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $566M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account